Articles by Lorenzo Falchi, MD
US Registry: Comparing Second-Line CAR-T Products in LBCL
ByMegan Melody, MD,Matthew Cortese, MD, MPH,Marco Davila, MD, PhD,Chelsea Peterson, DO,Lorenzo Falchi, MD,Lori Leslie, MD,Samuel Yamshon, MD Team Roswell presents ABC Consortium real-world data from 15 US centers comparing second-line outcomes with axi-cel, liso-cel, and a third CAR T product in large B-cell lymphoma, including manufacturing timelines, bridging therapy, response, survival, and key toxicities. The discussion highlights faster vein-to-vein time and fewer out-of-spec products with axi-cel, broadly similar efficacy between axi-cel and liso-cel, and higher rates of cytokine release syndrome/neurotoxicity with axi-cel alongside lower acute toxicity with liso-cel. Team NYC cross-examines the interpretation, especially the limited sample for the third product, and the panel pivots to practical post–CAR T survivorship issues like infections, hypogammaglobulinemia, IVIg use, and the need for more standardized supportive-care practices.
Real-World CAR-T Comparisons: Axi-cel vs Liso-cel in 2L LBCL
ByMegan Melody, MD,Matthew Cortese, MD, MPH,Marco Davila, MD, PhD,Chelsea Peterson, DO,Lorenzo Falchi, MD,Lori Leslie, MD,Samuel Yamshon, MD Team Roswell presents ABC Consortium real-world data from 15 US centers comparing second-line outcomes with axi-cel, liso-cel, and a third CAR T product in large B-cell lymphoma, including manufacturing timelines, bridging therapy, response, survival, and key toxicities. The discussion highlights faster vein-to-vein time and fewer out-of-spec products with axi-cel, broadly similar efficacy between axi-cel and liso-cel, and higher rates of cytokine release syndrome/neurotoxicity with axi-cel alongside lower acute toxicity with liso-cel. Team NYC cross-examines the interpretation, especially the limited sample for the third product, and the panel pivots to practical post–CAR T survivorship issues like infections, hypogammaglobulinemia, IVIg use, and the need for more standardized supportive-care practices.
Treatment Selection in Biologically Aggressive DLBCL
ByMegan Melody, MD,Matthew Cortese, MD, MPH,Marco Davila, MD, PhD,Chelsea Peterson, DO,Lorenzo Falchi, MD,Lori Leslie, MD,Samuel Yamshon, MD Teams from Roswell Park and New York City discuss advances in CAR T-cell therapy for large B-cell lymphoma. Team Roswell presents real-world data comparing second-line CAR T therapy with standard salvage chemotherapy and transplant approaches, highlighting improved event-free and overall survival outcomes with CAR T. Team NYC challenges the findings, raising questions about patient selection, treatment bias, and how real-world data should be interpreted alongside randomized clinical trial results.
There will be an unmet need for therapy in patients with aggressive lymphomas who did not benefit from therapy with bispecifics, CAR-T, chemotherapy, and targeted therapy.
Respiratory, viral, and bacterial infections have emerged as a toxicity of note during bispecific antibody treatment for indolent lymphoma.
Lorenzo Falchi, MD, highlighted the phase 1b/2 EPCORE NHL-2 and phase 1 BP41072 trials as prominent trials evaluating novel immunotherapy combinations in indolent lymphoma.
Bispecific antibodies have demonstrated adaptability and versatility when combined with immunotherapy and chemotherapy agents.
